[go: up one dir, main page]

PL2877467T3 - 2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4 - Google Patents

2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4

Info

Publication number
PL2877467T3
PL2877467T3 PL12740581T PL12740581T PL2877467T3 PL 2877467 T3 PL2877467 T3 PL 2877467T3 PL 12740581 T PL12740581 T PL 12740581T PL 12740581 T PL12740581 T PL 12740581T PL 2877467 T3 PL2877467 T3 PL 2877467T3
Authority
PL
Poland
Prior art keywords
azaindol
benzimidazoles
pad4 inhibitors
pad4
inhibitors
Prior art date
Application number
PL12740581T
Other languages
English (en)
Inventor
Stephen John Atkinson
Michael David Barker
Matthew Campbell
Hawa Diallo
Clement Douault
Neil Stuart Garton
John Liddle
Robert John Sheppard
Ann Louise Walker
Christopher Wellaway
David Matthew Wilson
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of PL2877467T3 publication Critical patent/PL2877467T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL12740581T 2012-07-26 2012-07-26 2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4 PL2877467T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/064649 WO2014015905A1 (en) 2012-07-26 2012-07-26 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors

Publications (1)

Publication Number Publication Date
PL2877467T3 true PL2877467T3 (pl) 2017-08-31

Family

ID=49996626

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12740581T PL2877467T3 (pl) 2012-07-26 2012-07-26 2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4

Country Status (22)

Country Link
US (4) US9127003B2 (pl)
EP (1) EP2877467B1 (pl)
JP (1) JP6063567B2 (pl)
KR (1) KR101916443B1 (pl)
CN (1) CN104470919B (pl)
AU (1) AU2012386257B2 (pl)
BR (1) BR112015001545B1 (pl)
CA (1) CA2879341C (pl)
CY (1) CY1118524T1 (pl)
DK (1) DK2877467T3 (pl)
ES (1) ES2609126T3 (pl)
HR (1) HRP20161530T1 (pl)
HU (1) HUE033294T2 (pl)
IN (1) IN2014KN02935A (pl)
LT (1) LT2877467T (pl)
PL (1) PL2877467T3 (pl)
PT (1) PT2877467T (pl)
RS (1) RS55684B1 (pl)
RU (1) RU2611010C2 (pl)
SI (1) SI2877467T1 (pl)
SM (2) SMT201700052T1 (pl)
WO (1) WO2014015905A1 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017024678A2 (pt) * 2015-05-21 2018-07-31 Glaxosmithkline Intellectual Property Development Limited derivados de benzoimidazol como inibidores de pad4
AR107030A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
CN109071497B (zh) * 2016-02-23 2021-10-22 帕德罗科治疗公司 Pad4杂芳基抑制剂
CN107188867A (zh) * 2016-03-14 2017-09-22 中国科学院天津工业生物技术研究所 精氨酸脱亚氨酶4的抑制剂
KR102398941B1 (ko) * 2016-07-27 2022-05-17 패들락 테라퓨틱스, 인코포레이티드 Pad4의 공유결합성 억제제
WO2018049296A1 (en) * 2016-09-12 2018-03-15 Padlock Therapeutics, Inc. Heteroaryl inhibitors of pad4
WO2018102262A1 (en) * 2016-12-02 2018-06-07 University Of Massachusetts Inhibitors of protein arginine deiminases (pads) and methods of preparation and use thereof
CN108689946B (zh) * 2017-04-12 2022-10-18 中国科学院上海药物研究所 2-取代硫基乙酰胺类化合物及其制备方法和应用
HUE067314T2 (hu) * 2017-09-22 2024-10-28 Jubilant Epipad LLC Heterociklusos vegyületek mint PAD gátlók
US11426412B2 (en) * 2017-10-18 2022-08-30 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
EP3707135A1 (en) 2017-11-06 2020-09-16 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
IL274762B2 (en) 2017-11-24 2023-10-01 Jubilant Episcribe Llc Novel heterocyclic compounds as prmt5 inhibitors
TWI762769B (zh) * 2018-02-26 2022-05-01 大陸商藥捷安康(南京)科技股份有限公司 肽醯精胺酸脫亞胺酶抑制劑及其用途
EP3765453A1 (en) 2018-03-13 2021-01-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
CA3102598A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
CN112566916B (zh) 2018-08-08 2023-10-20 百时美施贵宝公司 作为pad4抑制剂的经取代的噻吩并吡咯
KR102825194B1 (ko) * 2018-08-08 2025-06-24 브리스톨-마이어스 스큅 컴퍼니 Pad4 억제제로서의 치환된 벤즈이미다졸
SG11202101174RA (en) 2018-08-08 2021-03-30 Bristol Myers Squibb Co Indole and azaindole inhibitors of pad enzymes
EP3833439B1 (en) * 2018-08-08 2023-07-12 Bristol-Myers Squibb Company Benzimidazole inhibitors of pad enzymes
CN109369513B (zh) * 2018-11-20 2020-08-25 都创(上海)医药科技有限公司 一种fbdd常用分子片段的制备方法
JP7212781B2 (ja) 2018-12-19 2023-01-25 ディスアーム セラピューティクス, インコーポレイテッド 神経保護剤と組み合わせたsarm1の阻害剤
WO2021003078A1 (en) * 2019-07-03 2021-01-07 University Of Massachusetts Inhibitors of protein arginine deiminase 1 and methods of preparation and use thereof
CN112574230B (zh) * 2019-09-27 2022-10-28 药捷安康(南京)科技股份有限公司 肽酰精氨酸脱亚胺酶抑制剂及其用途
WO2021158840A1 (en) * 2020-02-06 2021-08-12 Bristol-Myers Squibb Company Macrocyclic pad4 inhibitors useful as immunosuppressant
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
CN111265526B (zh) * 2020-04-09 2021-03-19 黑龙江中医药大学 一种治疗胃癌的药物及其制备方法
WO2021222353A1 (en) * 2020-04-30 2021-11-04 Gilead Sciences, Inc. Macrocyclic inhibitors of peptidylarginine deiminases
IL301285A (en) 2020-09-10 2023-05-01 Precirix N V Antibody fragment against fap
WO2022059779A1 (ja) 2020-09-18 2022-03-24 大日本住友製薬株式会社 アミン誘導体
US11878965B2 (en) 2020-12-22 2024-01-23 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
TW202233174A (zh) 2020-12-22 2022-09-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
US20250136607A1 (en) 2021-11-15 2025-05-01 Regor Pharmaceuticals, Inc. Pad4 inhibitors and use thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
EP4518911A1 (en) 2022-05-02 2025-03-12 Precirix N.V. Pre-targeting
CN119604287A (zh) * 2022-05-26 2025-03-11 细胞基因公司 杂环pad4抑制剂
AU2023387505A1 (en) * 2022-11-24 2025-07-10 Helios Huaming Biopharma Co., Ltd. Selenium containing heterocycle compounds and use thereof
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
EE03997B1 (et) 1995-04-14 2003-04-15 Glaxo Wellcome Inc. Albuterooli doseeriv inhalaator
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
BR9913888A (pt) * 1998-09-18 2002-01-08 Basf Ag Composto, e, métodos de inibir a atividade da proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
ATE290865T1 (de) * 1999-10-19 2005-04-15 Merck & Co Inc Tyrosin kinase inhibitoren
NZ519121A (en) 1999-12-24 2004-05-28 Aventis Pharma Ltd Azaindoles useful as Syk kinase inhibitors
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
CA2544378A1 (en) 2003-11-03 2005-05-19 Glaxo Group Limited A fluid dispensing device
EP1687309A1 (en) 2003-11-17 2006-08-09 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7429611B2 (en) 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
WO2009042092A1 (en) 2007-09-25 2009-04-02 Merck & Co., Inc. 2-aryl or heteroaryl indole derivatives
US20090311217A1 (en) 2008-05-28 2009-12-17 Wyeth 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
RU2011106786A (ru) * 2008-07-23 2012-08-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы пиразолопиридинкиназы
SG174125A1 (en) * 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
US20100305093A1 (en) 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using

Also Published As

Publication number Publication date
KR20150038438A (ko) 2015-04-08
AU2012386257B2 (en) 2016-09-08
US10039755B2 (en) 2018-08-07
CA2879341C (en) 2019-06-11
RU2014152456A (ru) 2016-09-20
US20180161316A1 (en) 2018-06-14
BR112015001545A2 (pt) 2017-07-04
SI2877467T1 (sl) 2017-02-28
LT2877467T (lt) 2017-01-10
SMT201700052T1 (it) 2017-03-08
US9127003B2 (en) 2015-09-08
DK2877467T3 (en) 2017-02-13
AU2012386257A1 (en) 2015-03-12
CN104470919B (zh) 2016-07-06
CA2879341A1 (en) 2014-01-30
US20170119750A1 (en) 2017-05-04
JP2015522628A (ja) 2015-08-06
US20150175600A1 (en) 2015-06-25
ES2609126T3 (es) 2017-04-18
EP2877467A1 (en) 2015-06-03
SMT201700052B (it) 2017-03-08
CY1118524T1 (el) 2017-07-12
KR101916443B1 (ko) 2018-11-08
HRP20161530T1 (hr) 2017-02-10
US9833449B2 (en) 2017-12-05
WO2014015905A1 (en) 2014-01-30
US9518054B2 (en) 2016-12-13
IN2014KN02935A (pl) 2015-05-08
US20160009716A1 (en) 2016-01-14
PT2877467T (pt) 2017-01-02
EP2877467B1 (en) 2016-11-02
BR112015001545B1 (pt) 2022-07-05
CN104470919A (zh) 2015-03-25
JP6063567B2 (ja) 2017-01-18
RS55684B1 (sr) 2017-07-31
RU2611010C2 (ru) 2017-02-17
HUE033294T2 (en) 2017-11-28

Similar Documents

Publication Publication Date Title
PL2877467T3 (pl) 2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4
IL239193A0 (en) New Benzimidazole Derivatives as Kinase Inhibitors
SI2920149T1 (sl) Spojine 3-aminocikloalkila kot zaviralci receptorja ROR-gama-t in uporaba teh spojin
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
EP2832734A4 (en) HETEROCYCLIC COMPOUND
ZA201504980B (en) Heterocyclic compound
IL237475A0 (en) Pyrlotriazinone derivatives as pi3k inhibitors
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
ZA201406225B (en) Thiadiazolidinediones as gsk-3 inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
LT2912041T (lt) Tetrahidropiroltiazino dariniai kaip bace slopikliai
EP2866893A4 (en) HETEROCYCLIC GUANIDINE F1FO ATPASE INHIBITORS
EP2847186A4 (en) SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER
IL235919A0 (en) inhibitors of fbxo3
EP2847201A4 (en) 6-oxo-purin-phosphoribosyl INHIBITORS